Luca Murer

Luca Murer, Dr.

Department of Molecular Life Sciences

luca.murer@mls.uzh.ch

Publications:

Olszewski D, Georgi F, Murer L [...] Greber UF (2022).

High-content, arrayed compound screens with rhinovirus, influenza A virus and herpes simplex virus infections (https://doi.org/10.1038/s41597-022-01733-4)

Scientific Data, October 2022

 

Murer L, Volle R, Andriasyana V, [...] Greber UF (2022).

Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern (https://doi.org/10.1016/j.crviro.2022.100019)

Current Research in Virological Science, January 2022

 

Murer L, Petkidis A, Vallet T, Vignuzzi M, Greber UF (2022).

Chemical evolution of Rhinovirus identifies capsid-destabilizing mutations driving low pH-independent genome uncoating (https://doi.org/10.1128/JVI.01060-21)

Journal of Virology, January 2022

 

Georgi F, Andriasyan V, Witte R, Murer L, Hemmi S, Yu L, Grove M, Meili N, Kuttler F, Yakimovich A, Turcatti G, Greber UF (2020).

The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus (https://doi.org/10.1128/AAC.01002-20)

Antimicrobial Agents and Chemotherapy, August 2020

 

Georgi F, Kuttler F, Murer L, Andriasyan V, Witte R, Yakimovich A, Turcatti G, Greber UF (2020).

A high-content image-based drug screen of clinical compounds against cell transmission of adenovirus (https://doi.org/10.1038/s41597-020-00604-0)

Scientific Data, August 2020

 

Roulin PS, Murer LP, Greber UF (2018).

A Single Point Mutation in the Rhinovirus 2B Protein Reduces the Requirement for Phosphatidylinositol 4-Kinase Class III Beta in Viral Replication (https://doi.org/10.1128/JVI.01462-18)

Journal of Virology, December 2018